Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR) Short Interest Update

Posted by Lauren Steadman on Jun 11th, 2026

Cuprina Holdings (Cayman) LTD (NASDAQ:CUPR – Get Free Report) was the recipient of a significant decline in short interest in the month of May. As of May 29th, there was short interest totaling 85,189 shares, a decline of 69.4% from the May 14th total of 278,140 shares. Based on an average trading volume of 417,303 shares, the days-to-cover ratio is presently 0.2 days. Currently, 3.3% of the company’s shares are sold short.

Cuprina Holdings (Cayman) Price Performance

Shares of CUPR stock traded up $0.05 during mid-day trading on Thursday, reaching $2.31. The stock had a trading volume of 150,698 shares, compared to its average volume of 206,168. The company has a 50-day moving average price of $2.51. Cuprina Holdings has a 52-week low of $1.76 and a 52-week high of $76.00. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 0.07.

Cuprina Holdings (Cayman) (NASDAQ:CUPR – Get Free Report) last released its quarterly earnings data on Monday, April 27th. The company reported ($0.40) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cuprina Holdings (Cayman) in a research report on Friday, April 24th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Check Out Our Latest Stock Analysis on CUPR

Cuprina Holdings (Cayman) Company Profile

(Get Free Report)

We are a Singapore-based biomedical and biotechnology company that is dedicated to the development and commercialization of innovative products for the management of chronic wounds, as well as operating in the health and beauty sectors. Our expertise in biomedical research allows us to identify and utilize materials derived from natural sources to develop wound care products in the form of medical devices which meet international standards. We believe we will be able to build upon and leverage such expertise to develop innovative cosmeceutical products in the future.